Verrica Pharmaceuticals (FRA:1NE0) Net Interest Margin (Bank Only) %

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:1NE0 Verrica Pharmaceuticals Inc FRA:1NE0
44 GF Score
Price €4.64
GF Value €11.52
! 2 Warning Signs
View Full Analysis

What is Verrica Pharmaceuticals Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

FRA:1NE0
44GF Score
Verrica Pharmaceuticals Inc FRA:1NE0
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Verrica Pharmaceuticals (FRA:1NE0) Overvalued in 2026?

Based on GuruFocus' analysis, Verrica Pharmaceuticals stock appears to be undervalued. The current stock price of €4.64 is trading 59.8% below its estimated GF Value™ of €11.52.

Key valuation signals for FRA:1NE0:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: €11.52 vs. price of €4.64 (59.8% below fair value)
  • GF Score™: 44/100 with 2 warning signs

No single metric tells the full story. See the FRA:1NE0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Verrica Pharmaceuticals Business Description

Other Exchanges VRCA:USA
Address 44 West Gay Street, Suite 400, West Chester, PA, USA, 19380
Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.
44GF Score

Get the complete analysis for FRA:1NE0

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.64
Price
€11.52
GF Value